Galectin Therapeutics converted debt from five credit facilities, eliminating $105.8 million of debt, and reported $11.7 million of cash. It believes this funds planned operations through June 2027 and filed belapectin’s registrational Phase 3 protocol with FDA in 3Q 2026.
GALT · Galectin Therapeutics Inc
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this Form 10-Q.”View the 10-Q filed Nov 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 58%
- Last earnings
- Aug 14, 2025
- Latest filing
- 10-Q · Nov 16
- Price history
- Jan 2020 to Nov 2026
Latest documents
Galectin Therapeutics said FDA agreed on the primary endpoint and regulatory path for potential full approval of belapectin in MASH cirrhosis with portal hypertension; it filed a Phase 3 protocol in the third quarter of 2026 and is seeking partners.
Galectin Therapeutics will ask stockholders on December 3, 2026 to elect eleven directors, increase authorized common shares from 150,000,000 to 250,000,000, reserve 3,000,000 additional shares under its 2019 Omnibus Equity Incentive Plan, and ratify Cherry Bekaert LLP as auditor.
Galectin Therapeutics Inc. reported that belapectin 2mg/kg reduced esophageal varices by 49.3% in NAVIGATE’s per-protocol population (p-value<0.05) and by 68.1% among analyzed U.S. patients (p=0.02).
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Issuance of shares of common stock to Mr. Uihlein upon conversion | 34,376,167 | effective July 31, 2026 | — |
| lease cost | $18,000 | three months ended September 30, 2026 filing | — |
| placebo-adjusted improvement | 15.9% | at 18 months | — |
| remaining available under a line of credit | $10M | As of September 30, 2026 | — |
| shares of common stock issued under the 2020 At Market Agreement | 118,900 | three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GALT
this stock
Galectin Therapeutics Inc
|
$271.35M | -35.3% | — | — | 8.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 19
Galectin Therapeutics said FDA agreed on the primary endpoint and regulatory path for potential full approval of belapectin in MASH cirrhosis with portal hypertension; it filed a Phase 3 protocol in the third quarter of 2026 and is seeking partners.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GALT | -11.8% | -15.7% | +11.2% | -19.0% | -35.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -3.2% | -6.4% | +20.3% | -10.3% | -36.5% |